Poly(adenosine diphosphate [ADP] ̶ ribose) polymerase (PARP) inhibitors] (olaparib) – Approved for second-line treatment of deleterious or suspected deleterious germline BRCA mutated, HER2-negative high-risk early or metastatic breast cancer [9] For more information, see Breast Cancer, HER2 Br...
But I totally agree, given the choice between the two, I am also prioritizing the PARP inhibitor for the germline BRCA patients whose breast cancer is HR [hormone receptor]-positive. The exquisite synthetic lethality with a PARP inhibitor in the context of a germline mutation is one of the m...
The high incidence of breast cancer is the greastest threat to women’ health all over the world. Among them, HER-2 positive breast cancer has the characteristics of high malignancy, easy recurrence and metastasis, and poor prognosis. Traditional Chinese
AstraZeneca's Lynparza (olaparib), a poly ADP-ribose polymerase (PARP) inhibitor, has been added to the Korean Breast Cancer Society’s (KBCS) practice guidelines, two months after expanding its indication to postoperative adjuvant therapy in adult patients with breast cancer in Korea. AstraZenec...
breast tumours present as triple-negative breast cancer, a disease with poor prognosis; no targeted treatments have been approved specifically in this setting#In the adjuvant setting, a positive therapeutic effect of PARP inhibitors is anticipated in the well-defined population of patients with high-...
Lynparza boosts long-term survival in early breast cancer A single year of adjuvant treatment with AstraZeneca and MSD's PARP inhibitor Lynparza is still providing a survival benefit six years later. R&D Plants and vaccine adjuvants: BSI’s sustainable trees in a l... ...
Recently, the first PARP inhibitor has been approved for the treatment of BRCA1/2-associated ovarian cancer, while trials in early and metastatic breast cancer are ongoing. Lederman et al. compared toxicity of the PARP inhibitor olaparib in BRCA1/2 mutation carriers and sporadic patients with ...
Prior (neo) adjuvant chemotherapy and/or targeted therapy with a CDK4/6- or PARP- inhibitor is permitted. Study endpoints: The primary endpoint is invasive disease-free survival (IDFS), excluding second non-breast primary invasive cancers. Key secondary endpoints include distant relapse-free ...
The accumulation of 5-FU leads to caspase-3 and PARP activation, decreased Bcl-2 and increased Bad, ultimately leading to apoptosis of colorectal cancer cells [32]. The combination of EGCG and adriamycin also downregulated bcl-2 and increased the expression of bax and caspase-3, thus promoting...
In this study, we showed that adding a caspase-2 inhibitor diminished apoptosis in poly(I:C)-transfected RCC cells, and that selective knockdown of caspase-2 inhibited both apoptosis and activation of caspase-3, -8, and -9 in poly(I:C)-transfected RCC cells. These results suggest that ...